Skip to content

Efficacy of Laughter Yoga and anti-anxiety drugs on irritable bowel syndrome

Comparison of Laughter Yoga and anti-anxiety medication on anxiety and gastrointestinal symptoms of patients with irritable bowel syndrome

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170829035966N1
Enrollment
60
Registered
2018-01-17
Start date
2018-01-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome. Irritable bowel syndrome without diarrhoea ,Irritable bowel syndrome with diarrhoea

Interventions

Intervention 1: Intervention in the first intervention group:Laughter Yoga:Laughter Yoga combines unconditional laugh with yoga breathing and yoga stretching exercises, and people laughing without any
Behavior
Treatment - Drugs
Intervention in the second intervention group: Anti-anxiety treatment: Sertraline, 50 mg orally once a day for seven weeks
Control group: Symptomatic treatment with loperamide and hyoscine Loperamide: 2 mg orally three to four times a day for seven weeks Hyoscine: 20 mg orally four times a day for seven weeks
Intervention in the first intervention group:Laughter Yoga:Laughter Yoga combines unconditional laugh with yoga breathing and yoga stretching exercises, and people laughing without any jokes. Meetings

Sponsors

Vice Chancellor for research of Birjand University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients aged between 18 and 50 years old Patients who accepted to participate in the study after explaining the purposes of the study and advantages and disadvantages of the interventions There should be the possibility to keep the type and dose of the medications fixed during the study Patients who do not have psychotic or personality disorders Patients who do not have alarm signs including gastrointestinal bleeding, blood in stool, fever, weight loss, anemia, diarrhea at night, severe abdominal pain and so on

Exclusion criteria

Exclusion criteria: Patients who receive psychological treatments before entering the study Patients who have any other anatomical or functional gastrointestinal disorders

Design outcomes

Primary

MeasureTime frame
Irritable Bowel Syndrome severity. Timepoint: Before and right after the end of intervention. Method of measurement: Irritable Bowel Syndrome severity score system designed by Francis CY in 1997: mild (8 to 18) - moderate (18 to 30) - severe ( more than 30).

Secondary

MeasureTime frame
Anxiety severity. Timepoint: Before and right after the end of intervention. Method of measurement: Anxiety score from beck anxiety inventory.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Davoody Navid

Faculty of medicine, Birjand University of Medical Sciences, Birjand, South Khorasan, Iran.

Dr.n.davoody@gmail.com+98 51 3761 3026

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026